07:00 , Oct 5, 2015 |  BC Week In Review  |  Company News

BioNovion, Aduro Biotech deal

Aduro will also gain BioNovion’s antibody production technology, which is based on the clonal expansion of cultured B cells isolated from the spleen or lymph nodes of immunized mice, and five bispecific antibodies against undisclosed...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

BioNovion, Genmab deal

Genmab partnered with BioNovion to co-develop and co-commercialize bispecific antibodies targeting immune checkpoints. Both companies will contribute panels of antibodies to create the candidates using Genmab’s DuoBody technology. If the companies jointly select a product...
07:00 , Jun 19, 2014 |  BC Innovations  |  Targets & Mechanisms

CXCR2 antibodies for antitumor immunity

A National Cancer Institute team has found a new chemokine-regulated pathway of tumor immune evasion that could account for some patients' resistance to checkpoint inhibitor-based therapies. 1 By blocking CXC chemokine receptor 2 , the...